Previous 10 | Next 10 |
Verve Therapeutics (NASDAQ: VERV) , a clinical-stage gene-editing company focusing on cardiovascular disease, saw its shares race higher this week by a healthy 17.1%, according to data from S&P Global Intelligence . The biotech's stock jumped this week for three key reasons:...
Stifel has upgraded the gene-editing firm Verve Therapeutics ( NASDAQ: VERV ) to Buy from Neutral, citing the prospects for the biotech's lead product candidate, VERVE-101. The single-course therapy is currently undergoing heart-1, a Phase 1b clinical trial in New Zealand fo...
Shares of Verve Therapeutics are up 13% in late Tuesday afternoon trading following the release of preclinical data on VERVE-201 for a type of genetically high cholesterol (homozygous familial hypercholesterolemia). VERVE-201 is designed to permanently turn off the ANGPTL3 ...
CAMBRIDGE, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced new preclinical data supporting the nomination...
Verve Therapeutics press release ( NASDAQ: VERV ): Q2 GAAP EPS of -$0.84 misses by $0.20 . Cash, cash equivalents and marketable securities were $293.6 million as of June 30, 2022, as compared to $360.4 million as of December 31, 2021. For further details see: ...
Over $300 Million in Capital Added to Balance Sheet, Supporting an Operating Runway into Second Half of 2025 Patient Dosing Underway with Lead Candidate, VERVE-101, for Treatment of Heterozygous Familial Hypercholesterolemia; Regulatory Clearances in the United Kingdom and Unite...
Over the past few days, there have been some monster moves across a number of Russell 3,000 stocks. Taking a look at the Russell 3,000 members that had at least been cut in half from the time of the index’s high on January 3rd through the low on June 16th, followed by a rally o...
CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced upsize...
Verve Therapeutics (NASDAQ: VERV) , a biotech company specializing in gene-editing therapies to treat cardiovascular disease, has seen its shares rise 44.9% so far this week, according to data from S&P Global Intelligence . The stock closed last Friday at $23.71 and opened o...
Gainers: 1Life Healthcare ONEM +67% . Tabula Rasa HealthCare ( TRHC ) +27% . Cano Health ( CANO ) +15% . Repligen ( RGEN ) +15% . Oak Street Health ( OSH ) +10% . Losers: LumiraDx LMDX -25% . Verve Therapeuti...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities are encouraged to obtain additional informat...
2024-04-06 09:50:00 ET Verve Therapeutics (NASDAQ: VERV) saw its shares crater by 36% on April 2 when it reported that a serious mishap had occurred in one of its clinical trials. Understandably, investors may now question whether the gene-editing biotech has a shot at recovering, o...